FDA Approves Orphan Drug Status for Type 1 Diabetes Stem Cell Therapy
May 7, 2010 — The US Food and Drug Administration (FDA) has approved orphan drug designation for a stem cell therapy ( Prochymal ; Osiris Therapeutics, Inc) in patients with newly diagnosed type 1 diabetes mellitus. The product is an intravenous …
[Read the full article here]Related News:
Osiris Therapeutics Receives FDA Orphan Drug Designation For Stem Cell Treatment For Type 1 Diabetes
Tarix Pharma stem cell transplant drug wins orphan drug status
Athersys stem cells get orphan drug status for bone marrow disease